Literature DB >> 15025532

A novel, high-affinity, fluorescent progesterone receptor antagonist. Synthesis and in vitro studies.

Claudia Hödl1, Wolfgang S L Strauss, Reinhard Sailer, Christoph Seger, Rudolf Steiner, Ernst Haslinger, H Wolfgang Schramm.   

Abstract

The present paper describes the chemical synthesis and in vitro characterization of a novel, high-affinity, fluorescent progesterone receptor (PR) antagonist. The three-step synthesis was carried out starting from mifepristone. After demethylation with calcium oxide, the methylamino group was alkylated with 6-bromohexanol, and the resulting compound was reacted with fluorescein 5-isothiocyanate, yielding the fluorescein-mifepristone conjugate. Interaction of the conjugate as well as of its precursors with PR was determined in cell culture (alkaline phosphatase assay and transactivation assay). Antiprogestagenic activity of the intermediates were comparable to that of the parent compound. Even after attachment of the bulky fluorescein moiety, considerable antiprogestagenic activity was maintained. Microscopic studies revealed that fluorescence of the conjugate was almost confined to the nuclei of steroid hormone receptor-positive cells, whereas the nuclei of steroid hormone receptor-negative cells remained unstained. To our knowledge, this is the first report on a fluorescent ligand for PR suitable for studies in living cells. It is proposed that the present fluorescent PR antagonist might serve as a lead compound for the development of contrast agents for PR imaging, e.g., by near-infrared optical imaging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15025532     DOI: 10.1021/bc034169o

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  4 in total

1.  Synthesis, spectral characterization, and in vitro cellular activities of metapristone, a potential cancer metastatic chemopreventive agent derived from mifepristone (RU486).

Authors:  Jichuang Wang; Jianzhong Chen; Liyuan Wan; Jingwei Shao; Yusheng Lu; Yewei Zhu; Minrui Ou; Suhong Yu; Haijun Chen; Lee Jia
Journal:  AAPS J       Date:  2014-01-18       Impact factor: 4.009

2.  Fluorescent Human EP3 Receptor Antagonists.

Authors:  Miriam Tomasch; J Stephan Schwed; Karina Kuczka; Sascha Meyer Dos Santos; Sebastian Harder; Rolf M Nüsing; Alexander Paulke; Holger Stark
Journal:  ACS Med Chem Lett       Date:  2012-08-08       Impact factor: 4.345

3.  Novel RU486 (mifepristone) analogues with increased activity against Venezuelan Equine Encephalitis Virus but reduced progesterone receptor antagonistic activity.

Authors:  Aaron DeBono; David R Thomas; Lindsay Lundberg; Chelsea Pinkham; Ying Cao; J Dinny Graham; Christine L Clarke; Kylie M Wagstaff; Sharon Shechter; Kylene Kehn-Hall; David A Jans
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

4.  Fluorescent ligand for human progesterone receptor imaging in live cells.

Authors:  Roy Weinstain; Joan Kanter; Beth Friedman; Lesley G Ellies; Michael E Baker; Roger Y Tsien
Journal:  Bioconjug Chem       Date:  2013-04-29       Impact factor: 4.774

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.